WELL, AN ASSISTANT PROFESSOR AT THE UNIVERSITY OF NEW MEXICO HAS JUST RECEIVED A GRANT TO CONDUCT MORE RESEARCH ON THE ...

Erica spent years dealing with symptoms she didn’t realize were connected to polycystic ovarian syndrome until she was ...

In a multi-institutional study published in Science Direct, researchers revealed that testing urine-based tumor DNA (utDNA) ...

A diagnosis of 4 stage ovarian cancer can be devastating. However, advances in medical science are helping patients and offering them hope ...

In addition, patients treated with relacorilant plus nab-paclitaxel had a lower incidence of ascites (5.3 percent), than did patients who received nab-paclitaxel alone ... About Platinum-Resistant ...

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer. This is an ASCO Meeting ...

Led by Ludwig Princeton's Lydia Lynch and reported in the current issue of Science Immunology, the study details how ascites fluid-produced in large quantities as ovarian cancer spreads from the ...

By analyzing the contents of ascites fluid from ovarian cancer patients, the team identified a group of fat molecules called phospholipids as key drivers of this immune dysfunction. Dr. Karen Slattery ...

Discover how ascites disrupt immune cell function in late-stage ovarian cancer and how this could lead to new immunotherapy strategies. ... Ascites Weakens Immunity in Ovarian Cancer Patients Over 70% ...

Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer Go to source ). Over 70% of patients with ovarian cancer are diagnosed at an advanced stage, often presenting ...

By analyzing the contents of ascites fluid from ovarian cancer patients, they identified a group of fat molecules called phospholipids as key drivers of this immune dysfunction, suggesting that ...

Uptake of lipids from ascites drives NK cell metabolic dysfunction in ovarian cancer. Science Immunology , 2025; 10 (107) DOI: 10.1126/sciimmunol.adr4795 Cite This Page : ...